(Q46030058)

18 December 2017

meta-analysis

0 references

title

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. (English)

1 reference

18 December 2017

1 reference

Nicole R Pinelli

1

1 reference

18 December 2017

Raymond Cha

series ordinal

2

1 reference

18 December 2017

Morton B Brown

series ordinal

3

1 reference

18 December 2017

Linda A Jaber

series ordinal

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

28 October 2008

1 reference

18 December 2017

Annals of Pharmacotherapy

published in

1 reference

18 December 2017

volume

42

1 reference

18 December 2017

issue

11

1 reference

18 December 2017

page(s)

1541-1551

1 reference

18 December 2017

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

cites work

1 reference

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

21 January 2018

1 reference

Evolution of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

21 January 2018

1 reference

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea

21 January 2018

1 reference

Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo‐Asian patients

21 January 2018

1 reference

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

21 January 2018

1 reference

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

Addition of Rosiglitazone to Existing Sulfonylurea Treatment in Chinese Patients with Type 2 Diabetes and Exposure to Hepatitis B or C

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

21 January 2018

1 reference

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

21 January 2018

1 reference

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial.

21 January 2018

1 reference

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

21 January 2018

1 reference

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

21 January 2018

1 reference

An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes

21 January 2018

1 reference

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

21 January 2018

1 reference

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

21 January 2018

1 reference

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L198

1 reference

18 December 2017

PubMed ID

18957626

1 reference

18 December 2017